🇺🇸 LNTH — Lantheus Holdings, Inc.

Salud Mantener
← Volver

Precio actual

100,80 USD

Máx. histórico

123,62

845 días

Caída desde máximo

-18,46%

Rango 52 semanas

50,16 – 111,86

Variación hoy

+0,49%

Cierre anterior

100,31

Rango de hoy

100,26 – 100,83

Volumen hoy

748.573

Peor caída histórica

-78,62%

17/08/2015 → 08/02/2016

Recuperado en 202 días

Volatilidad anualizada ⓘ

63,44%

Información
Nombre completo
Lantheus Holdings, Inc.
Divisa
USD
Mercado
NasdaqGM
Sector
Salud
Industria
Drug Manufacturers - Specialty & Generic
Empleados
1.193
PER ⓘ
24,41 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
106,99 USD (puede no estar actualizado)
Primera cotización
25/06/2015
Precio actualizado
hace 14 horas
Sobre la empresa

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
04/03/2025 93,14 98,97 92,87 98,17 +3,49% 6,55% 1.215.700
03/03/2025 92,71 96,85 91,40 94,86 +1,11% 5,88% 1.336.700
28/02/2025 90,10 94,11 89,50 93,82 +2,55% 5,12% 987.800
27/02/2025 92,39 95,00 89,74 91,49 -1,89% 5,70% 1.118.400
26/02/2025 81,00 96,81 80,89 93,25 +16,49% 19,65% 2.650.200
25/02/2025 78,89 80,99 77,93 80,05 +1,39% 3,88% 1.645.500
24/02/2025 78,26 80,43 77,73 78,95 +0,92% 3,45% 913.400
21/02/2025 81,80 83,46 78,13 78,23 -3,23% 6,52% 899.300
20/02/2025 81,56 82,28 79,57 80,84 -0,68% 3,33% 880.300
19/02/2025 84,05 84,05 81,05 81,39 -2,42% 3,57% 571.700
18/02/2025 80,95 84,24 80,30 83,41 +4,34% 4,87% 1.252.200
14/02/2025 82,55 83,42 79,91 79,94 -2,46% 4,25% 737.300
13/02/2025 82,88 83,24 79,39 81,96 -0,17% 4,65% 775.900
12/02/2025 81,33 83,82 80,75 82,10 +0,22% 3,77% 706.100
11/02/2025 86,88 88,65 81,36 81,92 -5,74% 8,39% 1.371.900
10/02/2025 89,12 90,40 86,28 86,91 -2,03% 4,62% 910.100
07/02/2025 90,64 93,27 88,57 88,71 -2,41% 5,19% 675.300
06/02/2025 90,77 92,97 89,96 90,90 +0,51% 3,32% 846.800
05/02/2025 92,24 92,78 90,11 90,44 -1,48% 2,90% 708.700
04/02/2025 89,85 92,61 89,30 91,80 +2,52% 3,68% 863.200
03/02/2025 90,00 90,86 87,56 89,54 -3,21% 3,67% 641.500
31/01/2025 92,97 95,70 91,42 92,51 -0,30% 4,61% 790.700
30/01/2025 93,40 93,65 90,11 92,79 +0,28% 3,79% 831.700
29/01/2025 91,52 93,88 91,07 92,53 +1,54% 3,07% 938.000
28/01/2025 99,91 100,99 88,60 91,13 -7,30% 12,40% 1.565.600
27/01/2025 97,48 99,29 97,00 98,31 +0,83% 2,35% 474.200
24/01/2025 97,92 98,08 95,72 97,50 -0,13% 2,41% 510.000
23/01/2025 95,72 98,08 94,30 97,63 +2,35% 3,95% 655.800
22/01/2025 93,69 95,69 91,99 95,39 +1,42% 3,94% 685.200
21/01/2025 93,04 94,25 91,36 94,05 +2,82% 3,11% 828.200